학술논문

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies
Document Type
article
Source
The Journal of Infectious Diseases. 218(12)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
Immunology
Clinical Research
HIV/AIDS
Sexually Transmitted Infections
Infectious Diseases
6.1 Pharmaceuticals
Infection
Good Health and Well Being
Adult
Anti-HIV Agents
CD4 Lymphocyte Count
Drug Administration Schedule
Female
HIV Infections
HIV-1
Humans
Male
Middle Aged
Viral Load
Biological Sciences
Medical and Health Sciences
Microbiology
Biological sciences
Biomedical and clinical sciences
Health sciences
Language
Abstract
BackgroundHIV posttreatment controllers are rare individuals who start antiretroviral therapy (ART), but maintain HIV suppression after treatment interruption. The frequency of posttreatment control and posttreatment interruption viral dynamics have not been well characterized.MethodsPosttreatment controllers were identified from 14 studies and defined as individuals who underwent treatment interruption with viral loads ≤400 copies/mL at two-thirds or more of time points for ≥24 weeks. Viral load and CD4+ cell dynamics were compared between posttreatment controllers and noncontrollers.ResultsOf the 67 posttreatment controllers identified, 38 initiated ART during early HIV infection. Posttreatment controllers were more frequently identified in those treated during early versus chronic infection (13% vs 4%, P < .001). In posttreatment controllers with weekly viral load monitoring, 45% had a peak posttreatment interruption viral load of ≥1000 copies/mL and 33% had a peak viral load ≥10000 copies/mL. Of posttreatment controllers, 55% maintained HIV control for 2 years, with approximately 20% maintaining control for ≥5 years.ConclusionsPosttreatment control was more commonly identified amongst early treated individuals, frequently characterized by early transient viral rebound and heterogeneous durability of HIV remission. These results may provide mechanistic insights and have implications for the design of trials aimed at achieving HIV remission.